Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD06230 ...
Drug Name Nalmefene
Molecular Weight 339.435
Molecular Formula C21H25NO3
CAS Number 55096-26-9
SMILES [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C
External Links
DRUGBANK DB06230

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Water Solubility 130000.0 mg/L 130 mg/ml FDA Label
pKa 7.6 - 7.6 - FDA Label

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 131.0 ng.h/ml 131.0 ng.h/ml Oral single dose; DRUGBANK
AUC 183.4 ng.h/ml 170.3-196.5 ng.h/ml PO, oral; high-fat meal; high-fat meal ↑ ; DRUGBANK
Bioavailability 41.0 % 41 % PO, oral; DRUGBANK
Bioavailability 40.0 % 40.0 % PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 16.5 ng/ml 16.5 ng/ml Oral single dose; DRUGBANK
C Max 23.1 ng/ml 21.45-24.75 ng/ml PO, oral; high-fat meal; high-fat meal ↑ ; DRUGBANK
C Max 24.0 ng/ml 24±11 ng/ml Oral single dose; Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 17.0 ng/ml 17±6.3 ng/ml Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1.5 h Oral single dose; DRUGBANK
T Max 2.0 h 2 h PO, oral; high-fat meal; high-fat meal ↑ ; DRUGBANK
T Max 1.9 h 1.5-2.3 h IM,intramuscular injection; DRUGBANK
T Max 1.9 h 1.5-2.3 h subcutaneous injection, SC; DRUGBANK
T Max 2.5 h 2.5±0.58 h Oral single dose; Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 16.0 L/h 16.0 L/h PO, oral; DRUGBANK
Clearance 0.80 L/h/kg 0.8±0.2 L/h/kg Total clearance; intravenous injection, IV; normal,healthy; Male, men; DRUGBANK
Clearance 0.0800 L/h/kg 0.08±0.04 L/h/kg Renal clearance; intravenous injection, IV; normal,healthy; Male, men; DRUGBANK
Clearance 0.90 L/h/kg 15±4.5 ml/min/kg normal,healthy; adults; Male, men;  Female, women; metabolism of ugt; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.90 L/h/kg 15 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 3200.0 L ~3200 L PO, oral; DRUGBANK
Volume of Distribution 3.9 L/kg 3.9±1.1 L/kg Total volume of distribution; DRUGBANK
Volume of Distribution 8.6 L/kg 8.6±1.7 L/kg Steady state volume of distribution; DRUGBANK
Volume of Distribution 8.0 L/kg 8.0±1.8 L/kg normal,healthy; adults; Male, men;  Female, women; metabolism of ugt; RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 8.2 L/kg 8.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 12.5 h 12.5 h PO, oral; DRUGBANK
Half-life 10.8 h 10.8±5.2 h terminal half-life; adults; Male, men; intravenous injection, IV; DRUGBANK
Half-life 8.0 h 8.0±2.2 h normal,healthy; adults; Male, men;  Female, women; moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 8.8 h 8.8 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 17.0 % ~17 % Faeces excretion; DRUGBANK
Eliminate Route 9.6 % 9.6±4.9 % Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 37.5 % 30-45 % plasma proteins; DRUGBANK
Protein Binding 34.4 % 34.4±13.6 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1